The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development

Aljohani, Abrar I.; Toss, Michael S.; Green, Andrew R.; Rakha, Emad

Abstract

Background
Lymphovascular invasion (LVI) is regulated through complex molecular mechanisms. Cyclin B1 (CCNB1) was previously determined as being associated with LVI using large cohorts of breast cancer (BC) and artificial neural network (ANN) technique. In this study, we aimed to assess the association between CCNB1 and LVI, other clinicopathological and other LVI-related biomarkers at the molecular (RNA transcriptomic) and proteomic levels in BC.

Methods
Two transcriptomic BC cohorts (n = 2834) were used to assess the association between the expression of CCNB1 at the mRNA level and clinicopathological characteristics and patient outcome. Tissue microarrays (TMAs) from a well-characterised BC cohort (n = 2480) with long-term outcome were also used to assess the clinical significance of CCNB1 protein expression using immunohistochemistry.

Results
High CCNB1 mRNA expression was associated with aggressive tumour behaviour, including LVI, larger size, higher tumour grade, high lymph nodal stage, hormonal receptor negativity, HER2 positivity and poor clinical outcome (all p < 0.0001). Similarly, high CCNB1 protein expression was associated with higher tumour grade, hormonal receptor negativity and HER2 positivity (all p < 0.0001). Additionally, there was a significant association between CCNB1- and LVI-related biomarkers including N-cadherin, P-cadherin and TWIST2 at the transcriptomic and proteomic level. Multivariate analysis revealed that CCNB1 was an independent predictor of shorter BC-specific survival (HR = 1.3; 95% CI 1.2–1.5; p = 0.010).

Conclusion
CCNB1 is a key gene associated with LVI in BC and has prognostic value. More functional studies are warranted to unravel the mechanistic role of CCNB1 in the development of LVI.

Citation

Aljohani, A. I., Toss, M. S., Green, A. R., & Rakha, E. (2023). The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development. Breast Cancer Research and Treatment, 198, 423-435. https://doi.org/10.1007/s10549-022-06801-2

• Journal Article Type: Article
• Acceptance Date: Nov 4, 2022
• Online Publication Date: Nov 22, 2022
• Publication Date: 2023-04
• Deposit Date: Dec 22, 2022
• Publicly Available Date: Jan 3, 2023
• Journal: Breast Cancer Research and Treatment
• Print ISSN: 0167-6806
• Electronic ISSN: 1573-7217
• Peer Reviewed: Peer Reviewed
• Volume: 198
• Pages: 423-435
• DOI: https://doi.org/10.1007/s10549-022-06801-2
• Keywords: CCNB1; breast cancer; progression; LVI; prognosis
• Public URL: https://nottingham-repository.worktribe.com/output/15168398
• Publisher URL: https://link.springer.com/article/10.1007/s10549-022-06801-2